Synonyms: 3D-185 | 3D185
Compound class:
Synthetic organic
Comment: The chemical structure for segigratinib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor with [proposed antineoplastic action. A structure match via PubChem revealed segigratinib as the clinical candidate 3D185. 3D185 is a pan-FGFR inhibitor [1]. It also has inhibitory activity at CSF1R.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
3D185 is an active clinical candidate that has potential to treat advanced solid tumours. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04221204 | A Monotherapy in Subjects With Advanced Solid Tumors | Phase 1 Interventional | 3D Medicines | ||
NCT05039892 | Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma | Phase 2 Interventional | 3D Medicines |